Get involved in our
pivotal achievements

Versant Ventures is a leading healthcare investment firm committed to helping the next generation of great companies. The firm invests across the healthcare sector with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in Canada, the U.S. and Europe, Versant has built a team with deep investment, operating and scientific expertise that enables a hands-on approach to company building.

EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences and healthcare investment firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago, combining deep sector knowledge to provide an added value to the inventors that truly seek to make a difference for patients.

Versant Ventures is a leading healthcare investment firm committed to helping the next generation of great companies. The firm invests across the healthcare sector with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in Canada, the U.S. and Europe, Versant has built a team with deep investment, operating and scientific expertise that enables a hands-on approach to company building.

EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences and healthcare investment firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients. The team combines deep sector knowledge, analytical skills, and investment experience to provide the added value that inventors seek. EQT Life Sciences’ broad life sciences and healthcare network is highly complementary to EQT’s global healthcare sector franchise and makes EQT an even better and more innovative healthcare investor.

Founded in 2002, 5AM Ventures is a leading life science venture capital firm with ~$1 billion under management. With a focus on biopharmaceuticals, drug delivery technologies and life science instruments, 5AM strategically invests in first institutional VC rounds with significant reserves for follow-on investments. The team is comprised of 17 investment professionals with offices in San Francisco, CA and Boston, MA.

M Ventures is the strategic, corporate venture capital fund of Merck, investing in Biotechnology and Technology. We cover the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability.
We invest – with dual strategic and financial foci – into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence.
We take an active role in our portfolio companies and team up with entrepreneurs and co-investors to translate innovation towards commercial success.

Founded in 2002, 5AM Ventures is a leading life science venture capital firm with ~$1 billion under management. With a focus on biopharmaceuticals, drug delivery technologies and life science instruments, 5AM strategically invests in first institutional VC rounds with significant reserves for follow-on investments. The team is comprised of 17 investment professionals with offices in San Francisco, CA and Boston, MA.

M Ventures is the strategic, corporate venture capital fund of Merck, investing in Biotechnology and Technology. We cover the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability.
We invest – with dual strategic and financial foci – into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence.
We take an active role in our portfolio companies and team up with entrepreneurs and co-investors to translate innovation towards commercial success.

Andera Partners’ 15-person life sciences team brings together extensive experience in the life sciences industry, private equity and venture capital. Active since 2000, with offices in Paris and Munich, the team has raised over €1.1 billion through its BioDiscovery family of funds and is currently investing from its BioDiscovery 6 fund. Since inception, the BioDiscovery funds have invested in more than 80 European and U.S. biotech and medtech companies, with 22 IPOs and 22 M&As completed.

About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Fund of Investment and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them to clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds. For more information, please visit: www.bpifrance.com

Andera Partners’ 15-person life sciences team brings together extensive experience in the life sciences industry, private equity and venture capital. Active since 2000, with offices in Paris and Munich, the team has raised over €1.1 billion through its BioDiscovery family of funds and is currently investing from its BioDiscovery 6 fund. Since inception, the BioDiscovery funds have invested in more than 80 European and U.S. biotech and medtech companies, with 22 IPOs and 22 M&As completed.

About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Fund of Investment and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them to clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds. For more information, please visit: www.bpifrance.com

Revelation Partners provides flexible capital solutions to the healthcare ecosystem. We specialize in providing liquidity for illiquid, private holdings and growth capital to allow investors to maximize their return.
We invest broadly across all healthcare sub-sectors, including medical devices, diagnostics, biotech, healthcare technology, and healthcare services.
With decades of investing experience, deep sector expertise, an extensive industry network, and over $1.5B of committed capital, Revelation Partners is a trusted partner to healthcare companies, investors, founders, and funds.

Founded in 2016, today Indaco Venture Partners SGR is the largest independent Italian venture capital asset management company, with a strong specialization in companies that innovate electronics, robotics and new materials, medtech, biotech – pharma and digital. Indaco manages over EUR 350 million across its six funds.
Anchor institutional investors in Indaco SGR Funds include Intesa Sanpaolo, Fondazione Cariplo, European Investment Fund, CDP Venture Capital SGR, Quaestio SGR and Inarcassa.
In the digital sector, Indaco has an advisory partnership with growITup-Cariplo Factory; for Biotech and Pharma Indaco has a partnership with Università di Milano.
Indaco management has an extensive experience in venture investing in Italy and abroad and have executed a high number of successful exits, including IPOs and transactions with corporate partners.

Revelation Partners provides flexible capital solutions to the healthcare ecosystem. We specialize in providing liquidity for illiquid, private holdings and growth capital to allow investors to maximize their return.

We invest broadly across all healthcare sub-sectors, including medical devices, diagnostics, biotech, healthcare technology, and healthcare services.

With decades of investing experience, deep sector expertise, an extensive industry network, and over $1.5B of committed capital, Revelation Partners is a trusted partner to healthcare companies, investors, founders, and funds.

Founded in 2016, today Indaco Venture Partners SGR is the largest independent Italian venture capital asset management company, with a strong specialization in companies that innovate electronics, robotics and new materials, medtech, biotech – pharma and digital. Indaco manages over EUR 350 million across its six funds.
Anchor institutional investors in Indaco SGR Funds include Intesa Sanpaolo, Fondazione Cariplo, European Investment Fund, CDP Venture Capital SGR, Quaestio SGR and Inarcassa.
In the digital sector, Indaco has an advisory partnership with growITup-Cariplo Factory; for Biotech and Pharma Indaco has a partnership with Università di Milano.
Indaco management has an extensive experience in venture investing in Italy and abroad and have executed a high number of successful exits, including IPOs and transactions with corporate partners.

Launched end of 2022, XGEN Venture is specialized in venture capital investments across the life sciences sector. With offices based in Milan, Italy, the Team has over 15 years of investment activity together and significant direct experience in startup process and R&D effort behind novel solutions for high unmet medical needs.

Panakès Partners is a Venture Capital firm founded in 2015. We invest in the most innovative companies in the field of life sciences, both biotech and medtech, supporting teams developing revolutionary technologies and products, aiming to improve the lives of people around the world.

Launched end of 2022, XGEN Venture is specialized in venture capital investments across the life sciences sector. With offices based in Milan, Italy, the Team has over 15 years of investment activity together and significant direct experience in startup process and R&D effort behind novel solutions for high unmet medical needs.

Panakès Partners is a Venture Capital firm founded in 2015. We invest in the most innovative companies in the field of life sciences, both biotech and medtech, supporting teams developing revolutionary technologies and products, aiming to improve the lives of people around the world.

Angelini Ventures is the international venture capital firm of Angelini Industries, an Italian industrial group active in the healthcare, industrial technology, and consumer goods sectors.
Founded in 2022 with a commitment of €300 million, Angelini Ventures invests in Europe and North America in companies developing innovative solutions and ideas from BioTech to Digital Health to improve patient outcomes.
Headquartered in Rome, Angelini Ventures has a global team of 14 professionals from 10 different nationalities working in 9 cities (Rome, Milan, Singapore, Boston, Berlin, London, Copenhagen, Geneva and Turin).

Angelini Ventures is the international venture capital firm of Angelini Industries, an Italian industrial group active in the healthcare, industrial technology, and consumer goods sectors.
Founded in 2022 with a commitment of €300 million, Angelini Ventures invests in Europe and North America in companies developing innovative solutions and ideas from BioTech to Digital Health to improve patient outcomes.
Headquartered in Rome, Angelini Ventures has a global team of 14 professionals from 10 different nationalities working in 9 cities (Rome, Milan, Singapore, Boston, Berlin, London, Copenhagen, Geneva and Turin).

error: Content is protected !!!